AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow out of its China joint venture with Fosun Pharma. Korea's Yuhan ended an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback